US2023355603A1PendingUtilityA1

Psilocybin compositions

Assignee: TURTLE BEAR HOLDINGS LLCPriority: Jul 23, 2016Filed: Jul 18, 2023Published: Nov 9, 2023
Est. expiryJul 23, 2036(~10 yrs left)· nominal 20-yr term from priority
A61K 36/078A61K 36/07A61K 31/455A61K 31/4045A61K 31/675A61K 36/28A61K 36/16A61K 36/53A61K 36/537A61K 36/23A61K 36/9066A61K 36/80A61K 36/9068A61K 36/704A61K 36/82A61K 36/539A61K 36/899A61P 25/24A61K 31/357
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A pharmaceutical composition comprising of:
 0.1 mg to 10 mg of psilocybin or psilocin; and   1 mg to 50 mg of niacin.   
     
     
         2 . The composition of  claim 1 , further comprising:
 an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones.   
     
     
         3 . The composition of  claim 1 , further comprising one or more pharmaceutically acceptable excipients selected from acidifying agents, alkalizing agents, buffering agents, antimicrobial preservatives, antioxidants, or tablet disintegrants. 
     
     
         4 . The composition of  claim 1 , further comprising extracts of  Bacopa monnieri ,  Centella asiatica ,  Gingko biloba ,  Zingiber officinale ,  Ocimum sanctum ,  Polygonum cuspid atum ,  Origanum vulgare ,  Origanum onites ,  Rosmarinus officinalis ,  Rosmarinus eriocalyx ,  Curcuma longa ,  Camellia sinensis ,  Lavandula  species,  Scutellaria lateriflora ,  Avena sativa  and  Avena byzantine ,  Salvia divinorum ,  Banisteriopsis caapi ,  Psychotria  species,  Tabemanthe iboga ,  Voacanga africana ,  Tabemaemontana undulate ,  Ipomoea tricolor ,  Argyreia nervosa ,  Cannabis sativa ,  Cannabis indica ,  Cannabis ruderalis , or combinations thereof. 
     
     
         5 . The composition of  claim 1 , further comprising one or more of: mycelia, fruitbodies, mycelial extracts, or fruitbody extracts of fungi selected from  Antrodia ,  Beauveria ,  Copelandia ,  Cordyceps ,  Ganoderma ,  Grifola ,  Hericium ,  Inonotus ,  Isaria ,  Panaeolus ,  Phellinus , or combinations thereof.

Join the waitlist — get patent alerts

Track US2023355603A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.